ALNY Stock Recent News

CNBC's Jim Cramer explains why he is keeping an eye on shares of Alnylam Pharma.

Monday, Alnylam Pharmaceuticals Inc ALNY revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyopathy (ATTR-CM).

The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.

Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Alnylam Pharmaceuticals said on Monday that its drug vutrisiran met the main goal in a late-stage study testing it as a treatment for a type of heart disease.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular (CV) events du.

The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.

Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.

Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200 range, while a failure could lead to a drop towards $100. The key question is whether HELIOS-B shows a meaningful efficacy benefit for Amvuttra versus a high bar established by rival compounds.